JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Immune and Microbial Signatures Associated with PD-1 Blockade Sensitivity in a Preclinical Model for HPV+ Oropharyngeal Cancer

  • 0Cancer Biology Division, Comprehensive Cancer Center, University of Puerto Rico, San Juan, PR 00936, USA.
Cancers +

|

June 19, 2024

|

June 19, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Identifying specific immune cells and oral bacteria can predict head and neck squamous cell carcinoma (HNSCC) treatment response. This research offers potential biomarkers for improving Human Papillomavirus (HPV)-driven cancer therapy outcomes.

Area Of Science

  • Immunology
  • Microbiology
  • Oncology

Background

  • Head and neck squamous cell carcinoma (HNSCC) is a significant health concern, often linked to high-risk Human Papillomavirus (HPV) strains.
  • Current treatments using immune checkpoint inhibitors (e.g., PD-1 blockade) show limited efficacy in HNSCC patients, with response rates around 20-30%.

Purpose Of The Study

  • To identify biological markers associated with response to PD-1 blockade therapy in HNSCC.
  • To explore the role of immune cell phenotypes and oral microbiota in predicting treatment outcomes for HNSCC.

Main Methods

  • Analysis of immune cell frequencies, including activated T cells, B cells, dendritic cells, and myeloid-derived suppressor cells (MDSCs) in relation to therapy response.
  • Comparative analysis of oral microbiota composition in mice with tongue tumors treated with anti-PD-1 therapy, distinguishing between responders and non-responders.

Main Results

  • Therapy responders exhibited increased frequencies of activated CD27+ T cells, CD79a+ B cells, CD74+ antigen-presenting cells, and PD-L1+/PD-L2+ MDSCs.
  • Distinct oral microbiota profiles were observed: responders showed higher abundance of genera like *Allobaculum*, *Blautia*, *Faecalibacterium*, *Dorea*, and *Roseburia*, while non-responders had increased *Enterococcus*.

Conclusions

  • Immune phenotypes, protein expression levels, and specific bacterial abundances in the oral microbiota differ between responding and non-responding HNSCC models.
  • These findings suggest that specific immune cell profiles and oral bacteria can serve as predictive biomarkers for anti-PD-1 therapy response in HNSCC, potentially guiding novel therapeutic strategies.

Keywords: